Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 278.79% from the company’s current price. HC Wainwright also issued estimates for Aquestive Therapeutics’ FY2026 earnings at ($0.56) EPS.

Several other equities research analysts also recently weighed in on AQST. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target for the company. Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Aquestive Therapeutics currently has an average rating of “Buy” and a consensus target price of $10.57.

Aquestive Therapeutics Trading Up 3.9 %

AQST opened at $2.64 on Monday. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The company has a market cap of $261.02 million, a P/E ratio of -5.87 and a beta of 2.76. The company has a fifty day moving average price of $3.05 and a two-hundred day moving average price of $4.07.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million. On average, research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AQST. New York State Common Retirement Fund grew its position in Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Aquestive Therapeutics in the 4th quarter worth about $44,000. Two Sigma Advisers LP bought a new stake in Aquestive Therapeutics in the 4th quarter worth about $57,000. PKS Advisory Services LLC bought a new stake in Aquestive Therapeutics in the 4th quarter worth about $63,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Aquestive Therapeutics in the 4th quarter worth about $69,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.